AR129378A1 - Compuestos de indolinilo antivirales y usos de estos - Google Patents
Compuestos de indolinilo antivirales y usos de estosInfo
- Publication number
- AR129378A1 AR129378A1 ARP230101256A ARP230101256A AR129378A1 AR 129378 A1 AR129378 A1 AR 129378A1 AR P230101256 A ARP230101256 A AR P230101256A AR P230101256 A ARP230101256 A AR P230101256A AR 129378 A1 AR129378 A1 AR 129378A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- cycloalkyl
- haloalkyl
- alkyl
- optionally substituted
- Prior art date
Links
- -1 INDOLINYL COMPOUNDS Chemical class 0.000 title 1
- 230000000840 anti-viral effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción se relaciona con compuestos de indolinilo. La presente descripción se relaciona además con compuestos que inhiben el complejo helicasa-primasa viral. La presente descripción se relaciona además con el uso de los compuestos para la preparación de un medicamento para el tratamiento de enfermedades y/o afecciones mediante la inhibición del complejo helicasa-primasa viral. La presente descripción también se relaciona con el uso de esos compuestos en el tratamiento de infecciones virales. La presente descripción se relaciona además con intermediarios para su preparación y a composiciones farmacéuticas que contienen esos compuestos. Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable de este, en donde R¹ es un compuesto de fórmula (2) o (3); R²ᵃ, R²ᵇ, y R²ᶜ son cada uno independientemente H, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, -CN, haloalcoxi C₁₋₆, o -SCF₃; R³ᵃ y R³ᵇ son cada uno independientemente H, halógeno, alquilo C₁₋₆, o haloalquilo C₁₋₆; o R³ᵃ y R³ᵇ junto con el carbono al que se unen forman cicloalquilo C₃₋₆; en donde el cicloalquilo formado a partir de R³ᵃ y R³ᵇ puede sustituirse opcionalmente con uno a tres Z³, que pueden ser iguales o diferentes; Xᵃ y Xᵇ son cada uno independientemente O o CR⁷ᵃR⁷ᵇ; en donde R⁷ᵃ y R⁷ᵇ son cada uno independientemente H, alquilo C₁₋₆ o haloalquilo C₁₋₆; o R⁷ᵃ y R⁷ᵇ junto con el carbono al que se unen forman cicloalquilo C₃₋₆; en donde el cicloalquilo C₃₋₆ formado a partir de R⁷ᵃ y R⁷ᵇ puede sustituirse opcionalmente con uno a tres Z⁷, que pueden ser iguales o diferentes; R⁴ᵃ, R⁴ᵇ, y R⁴ᶜ son cada uno independientemente H, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, -CN, -SCF₃ o cicloalquilo C₃₋₆ opcionalmente sustituido con Z⁴; R⁵ es heteroarilo o arilo C₆₋₁₀; en donde el arilo o heteroarilo de R⁵ puede sustituirse opcionalmente con uno a tres Z⁵, que pueden ser iguales o diferentes; el heteroarilo de R⁵ es heteroarilo de 5 a 10 miembros que tiene uno a tres heteroátomos cada uno independientemente N, O, o S; R⁶ es H, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxialquilo C₂₋₈, o cicloalquilo C₃₋₆, en donde el cicloalquilo de R⁶ se sustituye opcionalmente con uno a tres Z⁶; y cada Z³, Z⁴, Z⁵, Z⁶, y Z⁷ es independientemente halógeno, -CN, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, o haloalcoxi C₁₋₆.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263344487P | 2022-05-20 | 2022-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129378A1 true AR129378A1 (es) | 2024-08-21 |
Family
ID=86851818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101256A AR129378A1 (es) | 2022-05-20 | 2023-05-19 | Compuestos de indolinilo antivirales y usos de estos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12522582B2 (es) |
| EP (1) | EP4526289A1 (es) |
| JP (1) | JP2025517423A (es) |
| KR (1) | KR20250016217A (es) |
| CN (1) | CN119546574A (es) |
| AR (1) | AR129378A1 (es) |
| AU (1) | AU2023272886A1 (es) |
| CA (1) | CA3255969A1 (es) |
| CL (1) | CL2024003512A1 (es) |
| CO (1) | CO2024016912A2 (es) |
| DO (1) | DOP2024000243A (es) |
| IL (1) | IL317009A (es) |
| MX (1) | MX2024014346A (es) |
| PE (1) | PE20251537A1 (es) |
| TW (2) | TW202502324A (es) |
| WO (1) | WO2023225162A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202540079A (zh) * | 2023-11-17 | 2025-10-16 | 美商基利科學股份有限公司 | 抗病毒吲哚啉基化合物及其用途 |
| WO2025104687A1 (en) | 2023-11-17 | 2025-05-22 | Gilead Sciences, Inc. | Solid forms of a hsv helicase primase inhibitor |
| WO2025172927A1 (en) | 2024-02-16 | 2025-08-21 | Assembly Biosciences, Inc. | Pharmaceutical compositions for herpes virus |
| WO2026015762A1 (en) | 2024-07-12 | 2026-01-15 | Gilead Sciences, Inc. | (r)-5-fluoro-2-methyl-1-((r)-5-(pyridin-2-yl)-2,3-dihydro-1 h-indene-2-carbonyl)indoline-6-sulfonamide for treatment of viral infections unresponsive to treatment with a first antiviral therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
| DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10038022A1 (de) | 2000-08-04 | 2002-02-14 | Bayer Ag | Inverse Thiazolylamid-Derivate |
| EP2914588B1 (en) * | 2012-11-03 | 2016-09-14 | Boehringer Ingelheim International GmbH | Inhibitors of cytomegalovirus |
| JP7150343B2 (ja) | 2017-01-09 | 2022-10-11 | フェーノ・セラピューティクス・カンパニー・リミテッド | チアゾール誘導体およびその使用 |
| CN112384512B (zh) | 2018-07-06 | 2022-03-29 | 辉诺生物医药科技（杭州）有限公司 | 噻唑类化合物的晶型及其应用 |
| WO2021126804A1 (en) * | 2019-12-18 | 2021-06-24 | Merck Sharp & Dohme Corp. | Indazole derivatives and methods of use thereof for the treatment of herpes viruses |
-
2023
- 2023-05-18 CA CA3255969A patent/CA3255969A1/en active Pending
- 2023-05-18 EP EP23731819.1A patent/EP4526289A1/en active Pending
- 2023-05-18 CN CN202380053428.XA patent/CN119546574A/zh active Pending
- 2023-05-18 JP JP2024568826A patent/JP2025517423A/ja active Pending
- 2023-05-18 KR KR1020247042167A patent/KR20250016217A/ko active Pending
- 2023-05-18 IL IL317009A patent/IL317009A/en unknown
- 2023-05-18 US US18/319,846 patent/US12522582B2/en active Active
- 2023-05-18 WO PCT/US2023/022679 patent/WO2023225162A1/en not_active Ceased
- 2023-05-18 AU AU2023272886A patent/AU2023272886A1/en active Pending
- 2023-05-18 PE PE2024002633A patent/PE20251537A1/es unknown
- 2023-05-19 TW TW113136044A patent/TW202502324A/zh unknown
- 2023-05-19 AR ARP230101256A patent/AR129378A1/es unknown
- 2023-05-19 TW TW112118660A patent/TWI859869B/zh active
-
2024
- 2024-11-18 CL CL2024003512A patent/CL2024003512A1/es unknown
- 2024-11-18 DO DO2024000243A patent/DOP2024000243A/es unknown
- 2024-11-19 MX MX2024014346A patent/MX2024014346A/es unknown
- 2024-12-10 CO CONC2024/0016912A patent/CO2024016912A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20251537A1 (es) | 2025-06-05 |
| EP4526289A1 (en) | 2025-03-26 |
| MX2024014346A (es) | 2025-02-10 |
| TW202502324A (zh) | 2025-01-16 |
| JP2025517423A (ja) | 2025-06-05 |
| TW202402270A (zh) | 2024-01-16 |
| CN119546574A (zh) | 2025-02-28 |
| TWI859869B (zh) | 2024-10-21 |
| DOP2024000243A (es) | 2025-05-15 |
| AU2023272886A1 (en) | 2024-12-05 |
| US20240101529A1 (en) | 2024-03-28 |
| IL317009A (en) | 2025-01-01 |
| US12522582B2 (en) | 2026-01-13 |
| KR20250016217A (ko) | 2025-02-03 |
| WO2023225162A1 (en) | 2023-11-23 |
| CO2024016912A2 (es) | 2024-12-19 |
| CL2024003512A1 (es) | 2025-05-02 |
| CA3255969A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129378A1 (es) | Compuestos de indolinilo antivirales y usos de estos | |
| AR118856A2 (es) | Compuestos terapéuticos | |
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR118374A1 (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| AR110674A1 (es) | Nucleósidos, nucleótidos sustituidos y análogos de los mismos | |
| AR089019A1 (es) | Derivados modificados de 4-fenil-piridina | |
| AR102722A2 (es) | Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit | |
| AR119728A1 (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR095034A1 (es) | El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| MX2018009944A (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico. | |
| AR093937A1 (es) | Compuestos quimicos | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR112831A1 (es) | Terapia de combinación usando un antagonista del receptor 2 de quimiocina (ccr2) y un inhibidor de pd-1 / pd-l1 | |
| PE20220252A1 (es) | Compuestos de pirrol | |
| AR119594A1 (es) | Derivados de tienopirimidina como inhibidores acc y usos de los mismos | |
| RU2019115059A (ru) | Модуляторы ror-гамма | |
| AR128440A1 (es) | Inhibidores de cinasas raf | |
| AR121554A1 (es) | Azálidos de urea inmunoduladores | |
| AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh | |
| AR112463A1 (es) | Derivados de propanamina para tratar el dolor y estados relacionados con dolor | |
| AR123543A1 (es) | DERIVADOS DE 2-(3-PIRIDIN-2-IL-4-QUINOLIN-4-IL-PIRAZOL-1-IL)-ACETAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b-1 / ALK5 | |
| AR128100A1 (es) | Compuestos para el tratamiento de la pérdida del cabello |